Cherie Lynn Ramirez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cherie Lynn Ramirez has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
J. Keith Joung
3 shared publications- J. Keith Joung
Molecular Pathology Unit, Massachusetts General Hospital
3 shared publications - Toni Cathomen
Medical Center - University of Freiburg
3 shared publications Brianna Desharnais
Simmons University, Boston, Massachusetts, USA
2 shared publicationsCyd Khayter
Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America
2 shared publicationsDaniel F Voytas
2 shared publications
Latest Publications
- Open Access
- 15 May 2021
- Published by International Society of Global Health in Journal of Global Health
- Vol. 11
Seeking truer measures of success: Moving toward more rigorous evaluations of industry-led access to medicines programs
- 15 May 2021
- Published by International Society of Global Health in Journal of Global Health
- Vol. 11
Open AccessSeeking truer measures of success: Moving toward more rigorous evaluations of industry-led access to medicines programs
- Open Access
- 1 March 2021
- Published by Elsevier in eClinicalMedicine
- Vol. 33
Executive summary: It's wrong not to test: The case for universal, frequent rapid COVID-19 testing
- 1 March 2021
- Published by Elsevier in eClinicalMedicine
- Vol. 33
Open AccessExecutive summary: It's wrong not to test: The case for universal, frequent rapid COVID-19 testing
- Open Access
- 5 April 2019
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (4) , e192224
Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes
Niacin, also known as nicotinic acid or vitamin B3, has a convoluted history in the United States. It had been available for decades as an over-the-counter product, used as a vitamin supplement and to regulate lipid levels, although its use was limited by a common unpleasant adverse effect: flushing.1 In 1997, a prescription extended-release version of niacin offered a lower risk of flushing and was approved by the US Food and Drug Administration (FDA) for use in the secondary prevention of cardiovascular disease (CVD).1 The approved indications for the drug were later expanded to include managing primary hyperlipidemia and mixed dyslipidemia, reducing triglyceride levels, treating atherosclerotic disease in combination with bile acid–binding resin, and regulating lipid levels and preventing cardiovascular events in combination with 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors (statins).2 However, in 2016, the FDA withdrew the latter indication based on the results of 2 large prospective trials including 29 087 patients.3,4 These trials showed that adding niacin to statins did not improve prevention or reduce mortality. In addition, niacin is now no longer recommended by clinical guidelines to prevent CVD.5 Yet, prescription niacin retains its other FDA-approved indications and is still used by hundreds of thousands of US patients,6 while many others use the over-the-counter versions.
- 5 April 2019
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (4) , e192224
Open AccessAssessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes
Niacin, also known as nicotinic acid or vitamin B3, has a convoluted history in the United States. It had been available for decades as an over-the-counter product, used as a vitamin supplement and to regulate lipid levels, although its use was limited by a common unpleasant adverse effect: flushing.1 In 1997, a prescription extended-release version of niacin offered a lower risk of flushing and was approved by the US Food and Drug Administration (FDA) for use in the secondary prevention of cardiovascular disease (CVD).1 The approved indications for the drug were later expanded to include managing primary hyperlipidemia and mixed dyslipidemia, reducing triglyceride levels, treating atherosclerotic disease in combination with bile acid–binding resin, and regulating lipid levels and preventing cardiovascular events in combination with 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors (statins).2 However, in 2016, the FDA withdrew the latter indication based on the results of 2 large prospective trials including 29 087 patients.3,4 These trials showed that adding niacin to statins did not improve prevention or reduce mortality. In addition, niacin is now no longer recommended by clinical guidelines to prevent CVD.5 Yet, prescription niacin retains its other FDA-approved indications and is still used by hundreds of thousands of US patients,6 while many others use the over-the-counter versions.
- Open Access
- 1 June 2018
- Published by Elsevier in The Lancet Global Health
- Vol. 6 (6) , e609-e610
Dispelling myths about drug procurement policy
- 1 June 2018
- Published by Elsevier in The Lancet Global Health
- Vol. 6 (6) , e609-e610
Open AccessDispelling myths about drug procurement policy
- 1 March 2015
- Published by American Public Health Association in American Journal of Public Health
- Vol. 105 (S1) , S50-S54
Public Health 101 Nanocourse: A Condensed Educational Tool for Non–Public Health Professionals
Graduate students and postdoctoral fellows—including those at the Harvard School of Public Health (HSPH)—have somewhat limited opportunities outside of traditional coursework to learn holistically about public health. Because this lack of familiarity could be a barrier to fruitful collaboration across disciplines, HSPH postdocs sought to address this challenge. In response, the Public Health 101 Nanocourse was developed to provide an overview of five core areas of public health (biostatistics, environmental health sciences, epidemiology, health policy and management, and social and behavioral sciences) in a two half-day course format. We present our experiences with developing and launching this novel approach to acquainting wider multidisciplinary audiences with the field of public health.
- 1 March 2015
- Published by American Public Health Association in American Journal of Public Health
- Vol. 105 (S1) , S50-S54
Public Health 101 Nanocourse: A Condensed Educational Tool for Non–Public Health Professionals
Graduate students and postdoctoral fellows—including those at the Harvard School of Public Health (HSPH)—have somewhat limited opportunities outside of traditional coursework to learn holistically about public health. Because this lack of familiarity could be a barrier to fruitful collaboration across disciplines, HSPH postdocs sought to address this challenge. In response, the Public Health 101 Nanocourse was developed to provide an overview of five core areas of public health (biostatistics, environmental health sciences, epidemiology, health policy and management, and social and behavioral sciences) in a two half-day course format. We present our experiences with developing and launching this novel approach to acquainting wider multidisciplinary audiences with the field of public health.
- Open Access
- 14 August 2013
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 41 (19) , e181
In silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-target sites
Gene-editing nucleases enable targeted modification of DNA sequences in living cells, thereby facilitating efficient knockout and precise editing of endogenous loci. Engineered nucleases also have the potential to introduce mutations at off-target sites of action. Such unintended alterations can confound interpretation of experiments and can have implications for development of therapeutic applications. Recently, two improved methods for identifying the off-target effects of zinc finger nucleases (ZFNs) were described–one using an in vitro cleavage site selection method and the other exploiting the insertion of integration-defective lentiviruses into nuclease-induced double-stranded DNA breaks. However, application of these two methods to a ZFN pair targeted to the human CCR5 gene led to identification of largely non-overlapping off-target sites, raising the possibility that additional off-target sites might exist. Here, we show that in silico abstraction of ZFN cleavage profiles obtained from in vitro cleavage site selections can greatly enhance the ability to identify potential off-target sites in human cells. Our improved method should enable more comprehensive profiling of ZFN specificities.
- 14 August 2013
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 41 (19) , e181
Open AccessIn silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-target sites
Gene-editing nucleases enable targeted modification of DNA sequences in living cells, thereby facilitating efficient knockout and precise editing of endogenous loci. Engineered nucleases also have the potential to introduce mutations at off-target sites of action. Such unintended alterations can confound interpretation of experiments and can have implications for development of therapeutic applications. Recently, two improved methods for identifying the off-target effects of zinc finger nucleases (ZFNs) were described–one using an in vitro cleavage site selection method and the other exploiting the insertion of integration-defective lentiviruses into nuclease-induced double-stranded DNA breaks. However, application of these two methods to a ZFN pair targeted to the human CCR5 gene led to identification of largely non-overlapping off-target sites, raising the possibility that additional off-target sites might exist. Here, we show that in silico abstraction of ZFN cleavage profiles obtained from in vitro cleavage site selections can greatly enhance the ability to identify potential off-target sites in human cells. Our improved method should enable more comprehensive profiling of ZFN specificities.
- 21 June 2012
- Published by Springer Nature
- p. 121-145
Engineered Zinc Finger Nucleases for Targeted Genome Editing
- 21 June 2012
- Published by Springer Nature
- p. 121-145
Engineered Zinc Finger Nucleases for Targeted Genome Editing
- Open Access
- 24 May 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (5) , e37877
Improved Somatic Mutagenesis in Zebrafish Using Transcription Activator-Like Effector Nucleases (TALENs)
Zinc Finger Nucleases (ZFNs) made by Context-Dependent Assembly (CoDA) and Transcription Activator-Like Effector Nucleases (TALENs) provide robust and user-friendly technologies for efficiently inactivating genes in zebrafish. These designer nucleases bind to and cleave DNA at particular target sites, inducing error-prone repair that can result in insertion or deletion mutations. Here, we assess the relative efficiencies of these technologies for inducing somatic DNA mutations in mosaic zebrafish. We find that TALENs exhibited a higher success rate for obtaining active nucleases capable of inducing mutations than compared with CoDA ZFNs. For example, all six TALENs tested induced DNA mutations at genomic target sites while only a subset of CoDA ZFNs exhibited detectable rates of mutagenesis. TALENs also exhibited higher mutation rates than CoDA ZFNs that had not been pre-screened using a bacterial two-hybrid assay, with DNA mutation rates ranging from 20%–76.8% compared to 1.1%–3.3%. Furthermore, the broader targeting range of TALENs enabled us to induce mutations at the methionine translation start site, sequences that were not targetable using the CoDA ZFN platform. TALENs exhibited similar toxicity to CoDA ZFNs, with >50% of injected animals surviving to 3 days of life. Taken together, our results suggest that TALEN technology provides a robust alternative to CoDA ZFNs for inducing targeted gene-inactivation in zebrafish, making it a preferred technology for creating targeted knockout mutants in zebrafish.
- 24 May 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (5) , e37877
Open AccessImproved Somatic Mutagenesis in Zebrafish Using Transcription Activator-Like Effector Nucleases (TALENs)
Zinc Finger Nucleases (ZFNs) made by Context-Dependent Assembly (CoDA) and Transcription Activator-Like Effector Nucleases (TALENs) provide robust and user-friendly technologies for efficiently inactivating genes in zebrafish. These designer nucleases bind to and cleave DNA at particular target sites, inducing error-prone repair that can result in insertion or deletion mutations. Here, we assess the relative efficiencies of these technologies for inducing somatic DNA mutations in mosaic zebrafish. We find that TALENs exhibited a higher success rate for obtaining active nucleases capable of inducing mutations than compared with CoDA ZFNs. For example, all six TALENs tested induced DNA mutations at genomic target sites while only a subset of CoDA ZFNs exhibited detectable rates of mutagenesis. TALENs also exhibited higher mutation rates than CoDA ZFNs that had not been pre-screened using a bacterial two-hybrid assay, with DNA mutation rates ranging from 20%–76.8% compared to 1.1%–3.3%. Furthermore, the broader targeting range of TALENs enabled us to induce mutations at the methionine translation start site, sequences that were not targetable using the CoDA ZFN platform. TALENs exhibited similar toxicity to CoDA ZFNs, with >50% of injected animals surviving to 3 days of life. Taken together, our results suggest that TALEN technology provides a robust alternative to CoDA ZFNs for inducing targeted gene-inactivation in zebrafish, making it a preferred technology for creating targeted knockout mutants in zebrafish.
- Open Access
- 28 February 2012
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 40 (12) , 5560-5568
Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects
Engineered zinc finger nucleases (ZFNs) induce DNA double-strand breaks at specific recognition sequences and can promote efficient introduction of desired insertions, deletions or substitutions at or near the cut site via homology-directed repair (HDR) with a double- and/or single-stranded donor DNA template. However, mutagenic events caused by error-prone non-homologous end-joining (NHEJ)-mediated repair are introduced with equal or higher frequency at the nuclease cleavage site. Furthermore, unintended mutations can also result from NHEJ-mediated repair of off-target nuclease cleavage sites. Here, we describe a simple and general method for converting engineered ZFNs into zinc finger nickases (ZFNickases) by inactivating the catalytic activity of one monomer in a ZFN dimer. ZFNickases show robust strand-specific nicking activity in vitro . In addition, we demonstrate that ZFNickases can stimulate HDR at their nicking site in human cells, albeit at a lower frequency than by the ZFNs from which they were derived. Finally, we find that ZFNickases appear to induce greatly reduced levels of mutagenic NHEJ at their target nicking site. ZFNickases thus provide a promising means for inducing HDR-mediated gene modifications while reducing unwanted mutagenesis caused by error-prone NHEJ.
- 28 February 2012
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 40 (12) , 5560-5568
Open AccessEngineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects
Engineered zinc finger nucleases (ZFNs) induce DNA double-strand breaks at specific recognition sequences and can promote efficient introduction of desired insertions, deletions or substitutions at or near the cut site via homology-directed repair (HDR) with a double- and/or single-stranded donor DNA template. However, mutagenic events caused by error-prone non-homologous end-joining (NHEJ)-mediated repair are introduced with equal or higher frequency at the nuclease cleavage site. Furthermore, unintended mutations can also result from NHEJ-mediated repair of off-target nuclease cleavage sites. Here, we describe a simple and general method for converting engineered ZFNs into zinc finger nickases (ZFNickases) by inactivating the catalytic activity of one monomer in a ZFN dimer. ZFNickases show robust strand-specific nicking activity in vitro . In addition, we demonstrate that ZFNickases can stimulate HDR at their nicking site in human cells, albeit at a lower frequency than by the ZFNs from which they were derived. Finally, we find that ZFNickases appear to induce greatly reduced levels of mutagenic NHEJ at their target nicking site. ZFNickases thus provide a promising means for inducing HDR-mediated gene modifications while reducing unwanted mutagenesis caused by error-prone NHEJ.